Swiss drugmaker Novartis has agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, marking a major consolidation in the pharmaceutical sector as of October 26, 2025.

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ...

Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions "Avidity has expanded the possibilities of what RNA therapeutics can ...

Novartis’ RNA production facility in Schweizerhalle, Switzerland. Novartis is acquiring Avidity Biosciences for approximately $12 billion, in a deal designed to bolster the buyer’s neuroscience ...

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports ...